Prostate Cancer & BPHArchives
Elevating the Patient Voice: Understanding Treatment Preferences in Patients with Advanced Prostate Cancer
Prostate Cancer & BPH 2 min.
Defined as taking five or more medications [1], polypharmacy affects approximately 44% of men over the age of 65 [2]. Polypharmacy is associated with treatment nonadherence, defined as not taking medication as prescribed, among elderly patients [3] and may portend negative outcomes in patients with prostate...
Photon counting detector CTA for prostate artery embolization pre-procedure planning and intra-procedural guidance
Prostate Cancer & BPH 5 min.
Prostate artery embolization (PAE) is a minimally invasive endovascular procedure included in Society of Interventional Radiology and American Urological Association guidelines for the treatment of benign prostatic hyperplasia (BPH) with moderate to severe lower urinary tract symptoms (LUTS) by international...
Novel Skp1 inhibitor has potent preclinical efficacy against castration-resistant prostate cancer
Prostate Cancer & BPH 7 min.
Prostate cancer (PCa) is the most frequently diagnosed non-cutaneous cancer and the second leading cause of cancer-related deaths in American men. In 2025, an estimated 313,780 new cases are expected to be diagnosed, with 35,770 deaths projected, primarily due to metastatic castration-resistant PCa (mCRPC)...
Association between serum 25-hydroxyvitamin D and prostate cancer in middle-aged and elderly Americans: a national population-based analysis of NHANES 2001–2018
Prostate Cancer & BPH 5 min.
Prostate cancer (PCa) remains the most commonly diagnosed malignancy and the second leading cause of cancer-related death among men in the United States, exerting substantial social and economic impacts. Between 2014 and 2019, its incidence increased annually by 3%, with nearly half of the patients presenting...
